Insulet Corp (PODD)
176.40
+1.97
(+1.13%)
USD |
NASDAQ |
May 06, 16:00
176.39
-0.01
(-0.01%)
After-Hours: 20:00
Insulet Enterprise Value: 12.91B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 12.91B |
| May 02, 2024 | 12.84B |
| May 01, 2024 | 12.62B |
| April 30, 2024 | 12.73B |
| April 29, 2024 | 12.62B |
| April 26, 2024 | 12.33B |
| April 25, 2024 | 12.19B |
| April 24, 2024 | 12.41B |
| April 23, 2024 | 12.41B |
| April 22, 2024 | 12.21B |
| April 19, 2024 | 12.34B |
| April 18, 2024 | 12.23B |
| April 17, 2024 | 12.34B |
| April 16, 2024 | 12.79B |
| April 15, 2024 | 12.87B |
| April 12, 2024 | 12.96B |
| April 11, 2024 | 13.27B |
| April 10, 2024 | 13.12B |
| April 09, 2024 | 13.16B |
| April 08, 2024 | 12.60B |
| April 05, 2024 | 12.25B |
| April 04, 2024 | 12.13B |
| April 03, 2024 | 12.24B |
| April 02, 2024 | 12.18B |
| April 01, 2024 | 12.47B |
| Date | Value |
|---|---|
| March 28, 2024 | 12.70B |
| March 27, 2024 | 12.54B |
| March 26, 2024 | 12.29B |
| March 25, 2024 | 12.23B |
| March 22, 2024 | 12.20B |
| March 21, 2024 | 12.36B |
| March 20, 2024 | 12.40B |
| March 19, 2024 | 12.64B |
| March 18, 2024 | 12.72B |
| March 15, 2024 | 12.31B |
| March 14, 2024 | 12.44B |
| March 13, 2024 | 12.99B |
| March 12, 2024 | 13.43B |
| March 11, 2024 | 13.38B |
| March 08, 2024 | 13.27B |
| March 07, 2024 | 12.98B |
| March 06, 2024 | 12.30B |
| March 05, 2024 | 12.17B |
| March 04, 2024 | 12.45B |
| March 01, 2024 | 12.55B |
| February 29, 2024 | 12.18B |
| February 28, 2024 | 12.15B |
| February 27, 2024 | 12.36B |
| February 26, 2024 | 12.52B |
| February 23, 2024 | 13.59B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.334B
Minimum
May 13 2019
23.79B
Maximum
May 12 2023
15.90B
Average
16.40B
Median
Enterprise Value Benchmarks
| Abbott Laboratories | 192.40B |
| Stryker Corp | 135.58B |
| Tandem Diabetes Care Inc | 2.768B |
| Becton Dickinson & Co | 82.66B |
| ResMed Inc | 32.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 103.30M |
| Revenue (Quarterly) | 509.80M |
| Total Expenses (Quarterly) | 403.40M |
| EPS Diluted (Quarterly) | 1.44 |
| Gross Profit Margin (Quarterly) | 70.85% |
| Profit Margin (Quarterly) | 20.26% |
| Earnings Yield | 1.65% |
| Operating Earnings Yield | 1.67% |
| Normalized Earnings Yield | 1.650 |